How to treat ANCA‑associated vasculitis: Practical messages from 2016 EULAR/ERA‑EDTA recommendations

Sznajd, Jan and Mukhtyar, Chetan ORCID: https://orcid.org/0000-0002-9771-6667 (2016) How to treat ANCA‑associated vasculitis: Practical messages from 2016 EULAR/ERA‑EDTA recommendations. Polskie Archiwum Medycyny Wewnetrznej, 126 (10). pp. 781-788. ISSN 0032-3772

Preview

PDF (inv_rev_Mukhtyar) - Published Version Available under License Creative Commons Attribution Non-commercial Share Alike. Download (167kB) | Preview

Abstract

The European League against Rheumatism (EULAR) with the European Renal Association - European Dialysis and Transplant Association recently published an update of 2009 EULAR recommendations with a focus on the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). In this article, we discuss the following key messages for clinical practice derived from these recommendations: 1) biopsy should be performed if possible to confirm new diagnosis or relapse; 2) glucocorticoid therapy is an extremely important adjunct to the management of AAV, but it is also responsible for the majority of adverse effects; the dose should be tapered to 7.5 to 10 mg/d at 3 to 5 months; 3) cyclophosphamide or rituximab are the mainstay of remission induction; 4) patients with major relapse should be treated like those with new disease, but rituximab is the preferred option in those patients who relapse after prior cyclophosphamide; 5) minor relapse should not be treated with glucocorticoid alone, and a change in immunosuppressive regimen should be considered; 6) rituximab can be used not only for remission induction but also for maintenance; 7) maintenance therapy should continue for at least 2 years, after which gradual taper could be considered; 8) while ANCA are extremely useful for diagnosis and rising ANCA levels seem to be associated with relapse, serial monitoring should not guide treatment decisions; 9) monitoring of AAV patients should be holistic with a structured assessment tool and monitoring for effects related to the vasculitis as well as treatment; 10) management should be either at or in conjunction with an expert center; and 11) patients should be involved in decision making and have access to educational resources.

Item Type:	Article
Uncontrolled Keywords:	aged,diagnosis,europe,humans,middle aged,practice guidelines as topic,societies, medical
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User:	LivePure Connector
Date Deposited:	27 Nov 2019 02:00
Last Modified:	22 Oct 2022 05:28
URI:	https://ueaeprints.uea.ac.uk/id/eprint/73093
DOI:	10.20452/pamw.3598

Downloads

Actions (login required)

View Item